BioCurex Presents Positive Results At International Oncology And Biomarkers Congress With Its RECAF Cancer Marker

Primezone Media Network

September 29, 2009

RICHMOND, British Columbia -- Whispering Oaks International, Inc., d/b/a Biocurex, announced today that it is making two presentations at the annual meeting of the International Society of Oncology and Biomarkers (ISOBM) being held this week in Amsterdam, The Netherlands. BioCurex's presentations address its RECAF cancer market test in combination with other currently used cancer markers: CA-125 for ovarian cancer and CEA for colorectal cancer.

The company's data show that combining RECAF with CA-125 detected 83% of ovarian cancers and combining RECAF with CEA detected 92% of colorectal cancers, with no false positives in either study. False positives are the most common reasons that most cancer marker tests are not useful for general screening. By combing the results of RECAF with these other cancer markers, the false positive rate was completely eliminated.

In addition, when the method was applied to very early stages of ovarian cancer, where a very high percentage of patients can be treated effectively, the combination test was still able to detect 75% of the cancer cases.

Dr. Moro, the Company's Chief Executive Officer, stated: "This is an important step ahead because CA-125 and CEA have been around for decades and combining them with RECAF provides a solution to the main problem with screenings: namely eliminating false positives while still detecting cancer cases at a high rate."

For more information on cancer markers, visit:

http://www.cancer.gov/cancertopics/factsheet/Detection/tumor-markers

http://www.cancer.net/portal/site/patient/menuitem.169f5d85214941ccfd748f68ee37a01d/?vgnextoid=5662e195df06e010VgnVCM100000ed730ad1RCRD

For information about the ISOBM visit www.isobm.org.

About BioCurex

BioCurex is a development stage diagnostics company focusing on development and commercialization of products for the early detection, diagnosis, and monitoring of recurrence of cancer. BioCurex has developed a blood test that can detect the presence of cancer in humans and companion animals using a new cancer marker named RECAF.

(C) 2009 Primezone Media Network. All Rights Reserved